The present work was undertaken with the aim to develop and validate a rapid and consistent UPLC method in which the peaks will be appear with short period of time as per ICH Guidelines. The proposed method was simple, fast, accurate and precise method for the Quantification of drug in the dosage form, bulk drug as well as for routine analysis in Quality control. UPLC method was developed and validated for simultaneous estimation of Metformin, Pioglitazone and Glimepiride in bulk drug and in combined dosage forms. The UPLC separation was achieved on a Symmetry C18 (2.1 x 100 mm, 1.7 mm, Make: BEH) or equivalent in an Isocratic Mode. The mobile phase was composed of Phosphate Buffer (25 %) whose pH was adjusted to 4.3 by using Ortho Phosphoric Acid and Methanol (75 %) [UPLC Grade] The flow rate was monitored at 0.25 ml per min. The wavelength was selected for the detection was 258 nm. The run time was 5 minutes. The retention time found for the drugs Metformin, Pioglitazone and Glimepiride were 0.002 minutes, 1.773 minutes and 2.409 minutes respectively. The % recovery was found to be 99.7 % -100.9 % for the drug Metformin. The % recovery was found to be 98.4 % -100.9 % for the drug Pioglitazone. The % recovery was found to be 99.9 % -101.2 % for the drug Glimepiride. The linearity was established in the range of 400 to 600 ppm for the drug Metformin and 12 to18 ppm for the drug Pioglitazone and 0.8 to 1.2 ppm for the drug Glimepiride. The LOD for the drugs Metformin, Pioglitazone and Glimepiride were found to be 0.12 µg/ml, 0.002 µg/ml and 0.002 µg/ml respectively. The LOQ for the drugs Metformin, Pioglitazone and Glimepiride were found to be 0.45 µg/ml, 0.15 µg/ml and 0.08 µg/ml respectively. The proposed method was adequate sensitive, reproducible, and specific for the determination of Metformin, Pioglitazone and Glimepiride in bulk as well as in Tablet dosage form. The validation of method was carried out utilizing ICH-guidelines. The described UPLC method was successfully employed for the analysis of pharmaceutical formulations containing combined dosage form. Overall the proposed method was found to be suitable and accurate for the Quantitative determination of the drug in Tablet dosage form. The method was simple, precise, accurate and sensitive and applicable for the simultaneous determination of Metformin, Pioglitazone and Glimepiride in bulk drug and in combined dosage forms.
INTRODUCTION
Diabetes is a lifelong (chronic) disease in which there are high levels of sugar in the blood. The diabetes is classified into three major types namely, type I, II, and gestational diabetes. Type II diabetes constitutes 90 % of the diabetic population. The combinational therapy for type II diabetes [1] [2] is frequently prescribed when mono therapy fails. The combination of Metformin (MET), Pioglitazone (PIO), and Glimepiride (GLIMP) is approved by FDA for treatment of type II diabetes 3 . Metformin is chemically, 1, 1-dimethyl biguanide hydrochloride. It is the first line drug of choice for the treatment of type2 diabetes. Metformin hydrochloride is a white crystalline powder. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. Bio analytical, HPLC, HPTLC and UVvisible spectrophotometry methods have been reported for its individual determination of Metformin and in combination with other drugs [4] [5] [6] [7] [8] . Glimepiride (is chemically 2-(3-ethyl-4-methyl-2-oxo-3 pyrroline-1-carboxamido) ethylphenylsulfonyl-3-(trans-4-methylcyclohexyl) urea. It is a medium to long acting sulphonyl urea anti-diabetic drug. Several Spectrophotometric methods, HPLC, HPTLC have been reported for estimation of Glimepiride [5] [6] [7] . Glimepiride is a white to yellowish-white, crystalline, odorless to practically odorless powder and is practically insoluble in water.
Pioglitazone is one of the PPAR-alpha agonist, insulin sensitizer used to reduce the insulin resistance. Pioglitazone hydrochloride is an odorless white crystalline powder. It is soluble in N, N-dimethyl formamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether. It is a thiazolidine Dione derivative and chemically
4-dione. HPLC and UV-visible spectrophotometry methods have been reported for its individual determination of Pioglitazone and in combination with other drugs [8] [9] [10] [11] [12] [13] [14] [15] . As per the literature, various methods are available for the estimation of these three drugs individually or in combination of two drugs in a pharmaceutical dosage form and also from biological samples. Very few methods are available for simultaneous estimation of all the three drugs together in a tablet dosage form. This paper describes a simple, precise, and accurate UPLC method for simultaneous estimation of MET, PIO, and GLIMP. Ultra performance liquid chromatography (UPLC) is a recent technique in liquid chromatography, which enables significant reductions in separation time and solvent consumption. Literature indicates that UPLC system allows about 9-fold decreases in analysis time as compared to the conventional HPLC system using 5 μm particle size analytical columns, and about 3-fold decrease in analysis time in comparison with 3 μm particle size analytical columns without compromise on overall separation. The chemical structures for the drug were represented in Figure 1, 2 [16] [17] [18] [19] [20] .
Apparatus and Chromatographic Conditions
The proposed method was performed on Ultra performance liquid chromatography equipped with Auto Sampler and DAD or UV detector. Chromatographic separation was achieved at ambient temperature on column Symmetry C 18 (2.1 x 100 mm, 1.7 mm, Make: BEH) or equivalent. The flow rate and run time was set to 0.25 ml/min and 5 minutes respectively. Analytical balance Afcoset ER-200A and pH meter Adwa -AD 1020 were used. The wavelength selected was 258 nm. The injection volume was 3 ml.
Preparation of Phosphate buffer and Mobile Phase
The buffer solution was prepared by dissolving accurately weighed 7.0 grams of Potassium Dihydrogen Phosphate and transferred into a clean and dry 1000 ml volumetric flask, dissolved and diluted with 1000 ml water [UPLC Grade]. The final pH of the buffer was adjusted to 4.3 by using Ortho Phosphoric Acid. The Mobile Phase was prepared by mixing 250 ml (25 %) of the above buffer and 750 ml of Methanol [UPLC Grade] (75 %) and degassed in an ultrasonic water bath for 10 minutes. Then the resultant solution was filtered through 0.45 µ filter under vacuum filtration. The Mobile phase was used as Diluent.
Preparation of the Metformin, Pioglitazone and Glimepiride Standard and Sample Solution Preparation of Stock solution
The stock solution was prepared by weighing accurately 500 mg Metformin, 15 mg Pioglitazone and 1 mg Glimepiride and transferred into a clean and dry 100 ml volumetric flask. About 70 ml of diluent was added and sonicated. The volume was made up to the mark with the same diluent. From the above prepared Stock solution pipette out 1.0 ml of solution and transferred into a clean and dry 10 ml volumetric flask, the diluent was added up to the mark to get final concentration.
Preparation of Sample Solution
The sample solution was prepared by weighing equivalently 1423.5 mg of Metformin, Pioglitazone and Glimepiride and transferred into a 100 ml clean and dry volumetric flask and about 70 ml of diluent was added and sonicated to dissolve it completely and the volume made up to the mark with the same solvent. From above prepared stock solution pipette out 1.0 ml of solution and transferred into a clean and dry 10 ml volumetric flask, the diluent was added up to the mark to get final concentration. The standard and sample solutions were injected five times and the peak areas were recorded. The mean and percentage relative standard deviation were calculated from the peak areas.
System Suitability
The Tailing factor for the peaks due to Metformin, Pioglitazone and Glimepiride in Standard solution should not be more than 2.0. The Theoretical plates for the Metformin, Pioglitazone and Glimepiride peaks in Standard solution should not be less than 2000. The system suitability of the method was checked by injecting five different preparations of the Metformin, Pioglitazone and Glimepiride standard. The parameters of system suitability were checked. 
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RESULTS AND DISCUSSION
In this UPLC method, chromatographic conditions were optimized to obtain best peak shape and resolution. Mobile phase selection of is based on the peak parameters like symmetry, theoretical plates, capacity factor tailing factor and ease of preparation and cost. Chromatograms of Standard and Formulation are given below in Figure 4 and Figure 6 respectively. The optimum wavelength for detection and quantification was set at 262 nm. The Ultra performance liquid chromatography (UPLC) methods was developed and validated for simultaneous estimation of Metformin, Pioglitazone and Glimepiride in bulk drug and in combined dosage forms. The UPLC separation was achieved on a Symmetry C 18 (2.1 x 100 mm, 1.7 mm, Make: BEH) or equivalent in an Isocratic Mode. The mobile phase was composed of Phosphate Buffer (25 %) whose pH was adjusted to 4. 3 by using Ortho Phosphoric Acid and Methanol (75 %) [UPLC Grade] The flow rate was monitored at 3.0 ml per min. The wavelength was selected for the detection was 258 nm. The run time was 5 minutes. The retention time found for the drugs Metformin, Pioglitazone and Glimepiride were 0.002 minutes, 1.773 minutes and 2.409 minutes respectively. It was represented in Figure 4 .
Method Validation
Method was validated according to ICH guidelines for validation of analytical procedures [21] [22] [23] .
Calibration Curve and Linearity
In order to test the linearity of the method, five dilutions of the working standard solutions for the drugs Metformin, Pioglitazone and Glimepiride were prepared. The linearity was established in the range of 400 to 600 ppm for the drug Metformin and 12 to18 ppm for the drug Pioglitazone and 0.8 to1.2 ppm for the drug Glimepiride. The data were represented in Table 10 , 11 and 12. Each of the dilution was injected into the column and the Linearity Curve was represented in Figure 7 , 8 and 9. The Correlation coefficient (R 2 ) should not be less than 0.999. The correlation coefficient obtained was 0.999 which was in the acceptance limit.
Precision
The Precision data for the drugs Metformin, Pioglitazone and Glimepiride were represented in Table 1 , 2 and 3. The % RSD for sample should be NMT 2. The % RSD for the standard solution was found to be 1.29, 0.27 and 1.73 for the drugs Metformin, Pioglitazone and Glimepiride respectively, which is within the limits hence the method was precise.
Intermediate Precision
When the drugs Metformin, Pioglitazone and Glimepiride were analyzed by the proposed method in the intra and interday (Ruggedness) variation, a low coefficient of variation was observed it was represented in Table 4 , 5 and 6 which shows that the developed UPLC method was highly precise. The % RSD was found to be 1.35, 1.59 and 1.12 for the drugs Metformin, Pioglitazone and Glimepiride respectively, which is within the limits.
Accuracy
The standard solution with Accuracy -80 %, Accuracy -100 % and Accuracy -120 % were injected into chromatographic system and calculated the amount found and amount added for Metformin, Pioglitazone and Glimepiride and further calculated the individual recovery and mean recovery values (Table 7, 8 and 9 ). The % recovery was found to be 99.7 % -100.9 % for the drug Metformin. The % recovery was found to be 98.4 % -100.9 % for the drug Pioglitazone. The % recovery was found to be 99.9 % -101.2 % for the drug Glimepiride.
Limit of Detection and Limit of Quantification
The Limit of detection and limit of quantification of the method were calculated basing on standard deviation of the response and the slope (s) of the calibration curve at approximate levels of the limit of detection and limit of quantification. The LOD for the drugs Metformin, Pioglitazone and Glimepiride were found to be 0.12 µg/ml, 0.002 µg/ml and 0.002 µg/ml respectively. The LOQ for the drugs Metformin, Pioglitazone and Glimepiride were found to be 0.45 µg/ml, 0.15 µg/ml and 0.08 µg/ml respectively. The Signal to noise ratio should be 3 for LOD. The results obtained were within the limit. The Signal to noise ratio should be 10 for LOQ solution. The results obtained were within the limit.
Robustness
The Robustness of the method was found out by testing the effect of small deliberate changes in the chromatographic conditions in the chromatographic conditions and the corresponding peak areas. The factors selected for this purpose were flow rate and percentage composition variation in Phosphate Buffer and Methanol [UPLC Grade] in the mobile phase. The method was found to be robust enough that the peak area was not apparently affected by small variation in the chromatographic conditions. The system suitability parameters were within the limits and shown in Table 13 , 14, 15, 16, 17 and 18.
CONCLUSION
It was concluded that the proposed new UPLC method developed for the quantitative determination of Metformin, Pioglitazone and Glimepiride in bulk as well as in its formulations was simple, selective, sensitive, accurate, precise and rapid. The method was proved to be superior to most of the reported methods. The mobile phases were simple to prepare and economical. The sample recoveries in the formulation were in good agreement with their respective label claims and they suggested non-interference of formulation excipients in the estimation. Hence the method can be easily adopted as an alternative method to report routine determination of Metformin, Pioglitazone and Glimepiride depending upon the availability of chemicals and nature of other ingredients present in the sample. The method also finds use in clinical, biological and pharmacokinetic studies for the drug Metformin, Pioglitazone and Glimepiride. The method was validated as per ICH guidelines, and validation acceptance criteria were met in all cases. The proposed method can be use in future for the clinical, biological and pharmacokinetic studies of Metformin, Pioglitazone and Glimepiride.
